The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

"FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease" was originally created and published by Pharmaceutical ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...

This Phase 3 study reaffirms the quality and therapeutic equivalence of YESINTEK compared to reference product, Stelara. The study demonstrated equivalent efficacy, safety, immunogenicity ...

Fresenius Kabi has launched the biosimilar Otulfi (ustekinumab-aauz)in the United States ... dose prefilled syringe for injection and a 130 mg/26 mL single dose vial for IV infusion. Otulfi in a 45 mg ...

single dose vial for IV infusion. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. Otulfi (ustekinumab-aauz ...

single dose vial for IV infusion. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar Otulfi ® ...

Ustekinumab is a human monoclonal antibody that ... for injection and a 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion. Otulfi ® in a 45 mg/0.5 mL single-dose vial for subcutaneous ...